@phdthesis{Schnaidt2007,
  author    = {Schnaidt, Ulrike},
  title     = {Das Plattenepithelkarzinom der Mundh{\"o}hle. Eine retrospektive Analyse der Therapieergebnisse und {\"U}berlebensraten bei neoadjuvanter Behandlung des W{\"u}rzburger Patientenkollektivs aus den Jahren 1993-2007},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-28006},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2007},
  abstract  = {In einem Zeitraum zwischen 1993 und 2007 wurden an der Klinik f{\"u}r Mund-, Kiefer-, und Gesichtschirurgie der Universit{\"a}t W{\"u}rzburg insgesamt 140 Patienten mit einem prim{\"a}ren Plattenepithelkarzinom der Oropharynxregion in eine retrospektive Studie einbezogen. Grundvoraussetzung war, dass alle Patienten eine neoadjuvante, pr{\"a}operative Radiochemotherapie mit einer Gesamtstrahlendosis von 40 Gy {\"u}ber 4 Wochen erhielten. Parallel zu den ersten 5 Bestrahlungstagen wurden den Patienten 60 mg/m² K{\"o}rperoberfl{\"a}che Carboplatin verabreicht. Ziel der Studie war, die Ergebnisse und {\"U}berlebensraten dieser multimodalen Therapie zu erforschen. Das Durchschnittsalter des Gesamtpatientengutes lag bei 55,6 Jahren, das Verh{\"a}ltnis zwischen M{\"a}nnern und Frauen betrug 4,4:1. Mit 37,9\% war die h{\"a}ufigste Tumorlokalisation der Mundboden. In 83,3\% der F{\"a}lle war das Plattenepithelkarzinom verhornend und zu 72,9\% m{\"a}ßig differenziert (G2). T4 Tumoren traten mit 52,1\% am h{\"a}ufigsten auf. Klinisch wurden 62,1\% pathologische Lymphknoten diagnostiziert. Nach der neoadjuvanten Radiochemotherapie wurde bei allen Patienten eine Operation durchgef{\"u}hrt. Pathohistologisch konnten 93,6\% R0-Resektionen nachgewiesen werden. Im weiteren Krankheitsverlauf erlitten 36,4\% der Patienten ein Rezidiv. Die 5-Jahres{\"u}berlebensrate der tumorassoziiert Verstorbenen betrug 64,1\%. Einen signifikanten Einfluss auf das {\"U}berleben zeigten das pT-Stadium (p< 0,01), das pN-Stadium (p< 0,01), das Grading (p= 0,031), die R0-Resektion (p< 0,01) sowie das Auftreten der Rezidive (p< 0,01). Beim {\"U}berlebensvergleich mit aktuellen Studien konnte diese signifikante Prognoseverbesserung best{\"a}tigt werden.},
  subject      = {Plattenepithelcarcinom},
  language  = {de}
}
@article{DiefenhardtMartinLudmiretal.2022,
  author    = {Diefenhardt, Markus and Martin, Daniel and Ludmir, Ethan B. and Fleischmann, Maximilian and Hofheinz, Ralf-Dieter and Ghadimi, Michael and Kosmala, Rebekka and Polat, B{\"u}lent and Friede, Tim and Minsky, Bruce D. and R{\"o}del, Claus and Fokas, Emmanouil},
  title     = {Development and validation of a predictive model for toxicity of neoadjuvant chemoradiotherapy in rectal cancer in the CAO/ARO/AIO-04 phase III trial},
  series = {Cancers},
  volume    = {14},
  journal   = {Cancers},
  number    = {18},
  issn      = {2072-6694},
  doi       = {10.3390/cancers14184425},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-288081},
  year      = {2022},
  abstract  = {Background: There is a lack of predictive models to identify patients at risk of high neoadjuvant chemoradiotherapy (CRT)-related acute toxicity in rectal cancer. Patient and Methods: The CAO/ARO/AIO-04 trial was divided into a development (n = 831) and a validation (n = 405) cohort. Using a best subset selection approach, predictive models for grade 3-4 acute toxicity were calculated including clinicopathologic characteristics, pretreatment blood parameters, and baseline results of quality-of-life questionnaires and evaluated using the area under the ROC curve. The final model was internally and externally validated. Results: In the development cohort, 155 patients developed grade 3-4 toxicities due to CRT. In the final evaluation, 15 parameters were included in the logistic regression models using best-subset selection. BMI, gender, and emotional functioning remained significant for predicting toxicity, with a discrimination ability adjusted for overfitting of AUC 0.687. The odds of experiencing high-grade toxicity were 3.8 times higher in the intermediate and 6.4 times higher in the high-risk group (p < 0.001). Rates of toxicity (p = 0.001) and low treatment adherence (p = 0.007) remained significantly different in the validation cohort, whereas discrimination ability was not significantly worse (DeLong test 0.09). Conclusion: We developed and validated a predictive model for toxicity using gender, BMI, and emotional functioning. Such a model could help identify patients at risk for treatment-related high-grade toxicity to assist in treatment guidance and patient participation in shared decision making.},
  language  = {en}
}
@article{LichthardtKerscherDietzetal.2016,
  author    = {Lichthardt, Sven and Kerscher, Alexander and Dietz, Ulrich A. and Jurowich, Christian and Kunzmann, Volker and von Rahden, Burkhard H. A. and Germer, Christoph-Thomas and Wiegering, Armin},
  title     = {Original article: role of adjuvant chemotherapy in a perioperative chemotherapy regimen for gastric cancer},
  series = {BMC Cancer},
  volume    = {16},
  journal   = {BMC Cancer},
  number    = {650},
  doi       = {10.1186/s12885-016-2708-0},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-147743},
  year      = {2016},
  abstract  = {Background Multimodal treatment strategies - perioperative chemotherapy (CTx) and radical surgery - are currently accepted as treatment standard for locally advanced gastric cancer. However, the role of adjuvant postoperative CTx (postCTx) in addition to neoadjuvant preoperative CTx (preCTx) in this setting remains controversial. Methods Between 4/2006 and 12/2013, 116 patients with locally advanced gastric cancer were treated with preCTx. 72 patients (62 \%), in whom complete tumor resection (R0, subtotal/total gastrectomy with D2-lymphadenectomy) was achieved, were divided into two groups, one of which receiving adjuvant therapy (n = 52) and one without (n = 20). These groups were analyzed with regard to survival and exclusion criteria for adjuvant therapy. Results Postoperative complications, as well as their severity grade, did not correlate with fewer postCTx cycles administered (p = n.s.). Long-term survival was shorter in patients receiving postCTx in comparison to patients without postCTx, but did not show statistical significance. In per protocol analysis by excluding two patients with perioperative death, a shorter 3-year survival rate was observed in patients receiving postCTx compared to patients without postCTx (3-year survival: 71.2 \% postCTx group vs. 90.0 \% non-postCTx group; p = 0.038). Conclusion These results appear contradicting to the anticipated outcome. While speculative, they question the value of post-CTx. Prospectively randomized studies are needed to elucidate the role of postCTx.},
  language  = {en}
}